Merck and Moderna's mRNA melanoma vaccine cut recurrence risk by 42% over two years in late-stage trials. The companies plan to file for approval soon and explore expansion into lung, kidney, and bladder cancers. Watch for regulatory decisions and pricing discussions, given the estimated $200,000 per dose cost.